Ivermectin: A Novel Method of Treatment of Nasal and Nasopharyngeal Myiasis
- 37 Downloads
To evaluate the efficacy of oral Ivermectin, in patients suffering from nasal and nasopharyngeal myiasis. This was a prospective study, comprising 80 patients of nasal and nasopharyngeal myiasis. Patients underwent clinical examination and nasal endoscopy at the time of presentation and findings were recorded. The patients were randomly divided in two groups. In group-I the patients underwent manual extraction of the maggots after instillation of chloroform and turpentine oil mixture, whereas the group-II patients underwent manual extraction with administration of two doses (24 h apart) of oral Ivermectin (6 mg each). The patients were instructed to record the time when they noticed shedding of maggots, and evaluated for the clearance of maggots by endoscopy after 24, 48 h and 7 days after the initial examination. The mean maggot shedding time (by t test) in Group-I was 41.23 ± 4.23 h and in Group-II was 24.60 ± 3.15 h. The difference being highly significant statistically, (p = 0.0001). The endoscopic clearance of maggots (by Chi square test) between the two group of patients was also statistically significant at 24 and 48 h with p value of (p = 0.002) and (p = 0.006) respectively. Oral Ivermectin was effective in treating nasal and nasopharyngeal myiasis, in terms of early clearance, decreased morbidity and less hospital stay. We conclude that oral Ivermectin can be used as a safe and effective method for the treatment of nasal & nasopharyngeal myiasis.
KeywordsNasopharyngeal myiasis Nasal myiasis Ivermectin Ivermectin in nasal myiasis
Compliance with Ethical Standards
Conflict of interest
The Author declares that they have no conflict of interest.
Statement of Human Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.Introduction to myiasis: natural history museum. Nhm.ac.uk. Retrieved 11 May 2013Google Scholar
- 6.Harwood RF, James MT (1969) Entomology in human and animal health. Macmillan, New York, p 548Google Scholar
- 7.Zumpt F (1965) Myiasis in man and animals in the old world. Butterworths, London, p 267Google Scholar
- 9.James MT (1947) The flies that cause myiasis in man. Department of Agriculture, Misc, Publication No. 63, Washington, USAGoogle Scholar
- 10.Fisher MH, Mrozik H (1992) The chemistry and pharmacology of avermectins. Annu Rev Pharmacol Toxicol 32:537–553. https://doi.org/10.1146/annurev.pa.32.040192.002541 CrossRefPubMedGoogle Scholar
- 13.Sahay LK (1959) A study of maggots and their otolaryngeal manifestations. Indian J Otolaryngol 11:146–168Google Scholar
- 18.CDC (2012) Increasing prevalence of diagnosed diabetes-United States and Puerto Rico 1995–2010. MMWR 61(45):918–921Google Scholar
- 19.CDC. Diabetes data and trends. Atlanta, GA: US Department of Health and Human Services, CDC, National Diabetes Surveillance System. www.cdc.gov/diabetes/statistics. Accessed 8 Nov 2012
- 20.Geiss LS, Cowie C (2011) Type 2 diabetes and persons at high risk of diabetes. In: Venkat Narayan KM, Williams D, Gregg EW, Cowie C (eds) Diabetes public health: from data to policy. Oxford University Press, New York, pp 15–32Google Scholar
- 28.Bennet DG (1986) Clinical pharmacology of ivermectin. JAVMA 189:100–103Google Scholar